Study of Predictive Factors of Chemoresistance in Ovarian Cancer

Completed

• Conditions: Ovarian Cancer

• Registration Number: NCT02878122
• Lead Sponsor: Rennes University Hospital

Brief Summary

Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03
• Study First Submitted: 2016-08-22
• Study First Submitted QC: 2016-08-24
• Study First Posted: 2016-08-25
• Primary Completion: 2020-03
• Study Completion: 2020-03
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-16
• Last Update Posted: 2021-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 13

Inclusion Criteria

• patient > 18 years of age
• patient with histological proven epithelial ovarian cancer

Exclusion Criteria

• patients who can not give their own consent
• patients without ovarian cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chemoresistance defined by clinical recurrence	6 months after the end of chemotherapy
Chemoresistance defined by biological recurrence	6 months after the end of chemotherapy
Chemoresistance defined by radiological recurrence	6 months after the end of chemotherapy

Trial Locations

Locations (1)

LAVOUE; 🇫🇷 Rennes, France